BCL2A1 and acute myeloid leukemia: Additionally, AML patients’ samples display a differential expression of BCL2-A1 in resistant cells [76,126], which suggests a potential for synergy between BCL-2 and BCL2A1 inhibitors in selective AML subsets [126].